Technologies

Midazolam has previously been administered via a variety of routes, including the intranasal route, for the management of acute seizures. Researchers at the University of California, Davis researchers have demonstrated in rodent chemoconvulsant models that inhaled intrapulmonary (nebulized) midazolam can protect against seizures more rapidly and more potently than when administered by other routes. The lung is highly vascularized and the thin alveolar epithelium represents a large absorptive surface. Blood exiting the lung is delivered directly to the brain so that the seizure protection conferred by intrapulmonary midazolam occurs with very short latency. Unexpectedly, midazolam delivered via the lung is more potent than when administered by other routes, including intravenously.